These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18245661)

  • 1. Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib.
    Franceschino A; Tornaghi L; Benemacher V; Assouline S; Gambacorti-Passerini C
    Haematologica; 2008 Feb; 93(2):317-8. PubMed ID: 18245661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib.
    Woo SM; Huh CH; Park KC; Youn SW
    J Dermatol; 2007 Oct; 34(10):724-6. PubMed ID: 17908148
    [No Abstract]   [Full Text] [Related]  

  • 3. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
    François H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
    Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia.
    Oztas P; Erbasi S; Lenk N; Polat M; Han O; Artuz F; Alli N
    Acta Derm Venereol; 2006; 86(2):174-5. PubMed ID: 16648930
    [No Abstract]   [Full Text] [Related]  

  • 5. Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib.
    Breccia M; D'Elia GM; D'Andrea M; Latagliata R; Alimena G
    Eur J Haematol; 2005 Jan; 74(1):89-90. PubMed ID: 15613116
    [No Abstract]   [Full Text] [Related]  

  • 6. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
    Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
    Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitiligo-like lesions in an adult patient treated with Imatinib mesylate.
    Cerchione C; Fabbricini R; Pane F; Luciano L
    Leuk Res; 2009 Aug; 33(8):e104-5. PubMed ID: 19232719
    [No Abstract]   [Full Text] [Related]  

  • 8. Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec).
    Gordon JK; Magid SK; Maki RG; Fleisher M; Berman E
    Leuk Res; 2010 Jun; 34(6):827-9. PubMed ID: 19963273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?
    Breccia M; Alimena G
    Leuk Res; 2009 Nov; 33(11):1450-1. PubMed ID: 19615745
    [No Abstract]   [Full Text] [Related]  

  • 10. Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia.
    Galanopoulos A; Papadhimitriou SI; Kritikou-Griva E; Georgiakaki M; Anagnostopoulos NI
    Ann Hematol; 2009 Mar; 88(3):281-2. PubMed ID: 18726593
    [No Abstract]   [Full Text] [Related]  

  • 11. Pregnancy among patients with chronic myeloid leukemia treated with imatinib.
    Ault P; Kantarjian H; O'Brien S; Faderl S; Beran M; Rios MB; Koller C; Giles F; Keating M; Talpaz M; Cortes J
    J Clin Oncol; 2006 Mar; 24(7):1204-8. PubMed ID: 16446320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission.
    Khouri S; Kotliroff A; Lishner M; Amital H
    Isr Med Assoc J; 2008 Apr; 10(4):320-1. PubMed ID: 18548994
    [No Abstract]   [Full Text] [Related]  

  • 13. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of imatinib in chronic myeloid leukemia in blastic crisis presenting as cholestatic jaundice.
    Ramamoorthy SK; Pandita R; Prakash A; Ramaswamy NV; Al Bahar S
    Acta Haematol; 2007; 118(3):141-5. PubMed ID: 17804901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib.
    Breccia M; Carmosino I; Russo E; Morano SG; Latagliata R; Alimena G
    Eur J Haematol; 2005 Feb; 74(2):121-3. PubMed ID: 15654902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience.
    Breccia M; Cannella L; Frustaci A; Stefanizzi C; Levi A; Alimena G
    Leuk Res; 2008 May; 32(5):835-6. PubMed ID: 17905431
    [No Abstract]   [Full Text] [Related]  

  • 17. [Intestinal bleeding during the treatment of chronic myeloid leukemia with imatinib mesylate].
    Yokote T; Akioka T; Nakayama S; Oka S; Hara S; Yamano T; Tsuji M; Hanafusa T
    Rinsho Ketsueki; 2005 Sep; 46(9):1060-4. PubMed ID: 16440765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib and pregnancy.
    Ali R; Ozkalemkas F; Ozcelik T; Ozkocaman V; Ozkan A
    J Clin Oncol; 2006 Aug; 24(23):3812-3; author reply 3813. PubMed ID: 16896012
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis.
    Ozdemir E; Koc Y; Kansu E
    Am J Hematol; 2006 Jun; 81(6):474. PubMed ID: 16680756
    [No Abstract]   [Full Text] [Related]  

  • 20. Imatinib mesylate as a cause of acute liver failure.
    Cross TJ; Bagot C; Portmann B; Wendon J; Gillett D
    Am J Hematol; 2006 Mar; 81(3):189-92. PubMed ID: 16493605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.